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C-reactive protein (CRP), a component of the innate immune system, is an
antipneumococcal plasma protein. Human CRP has been shown to protect mice against
infection with lethal doses of Streptococcus pneumoniae by decreasing bacteremia.
in vitro, CRP binds to phosphocholine-containing substances, such as pneumococcal
C-polysaccharide, in a Ca2+ -dependent manner. Phosphocholine-complexed human
CRP activates the complement system in both human and murine sera. The mechanism
of antipneumococcal action of CRP in vivo, however, has not been defined yet.
In this study, we tested a decades-old hypothesis that the complement-activating
property of phosphocholine-complexed CRP contributes to protection of mice against
pneumococcal infection. Our approach was to investigate a CRP mutant, incapable
of activating murine complement, in mouse protection experiments. We employed
site-directed mutagenesis of CRP, guided by its three-dimensional structure, and
identified a mutant H38R which, unlike wild-type CRP, did not activate complement
in murine serum. Substitution of His38 with Arg in CRP did not affect the pentameric
structure of CRP, did not affect the binding of CRP to pneumococci, and did not decrease
the stability of CRP in mouse circulation. Employing a murine model of pneumococcal
infection, we found that passively administered H38R CRP failed to protect mice against
infection. Infected mice injected with H38R CRP showed no reduction in bacteremia
and did not survive longer, as opposed to infected mice treated with wild-type CRP.
Thus, the hypothesis that complement activation by phosphocholine-complexed CRP
is an antipneumococcal effector function was supported. We can conclude now that
complement activation by phosphocholine-complexed CRP is indeed essential for
CRP-mediated protection of mice against pneumococcal infection.
Keywords: C-reactive protein, acute phase response, complement, inflammation, pneumococcal infection

INTRODUCTION
C-reactive protein (CRP) is a multifunctional component of the acute phase response and innate
host defense machinery (1, 2). CRP is composed of five identical subunits arranged as a cyclic
pentamer (3, 4). Each subunit has a phosphocholine (PCh)-binding site through which CRP binds
to PCh-containing substances such as C-polysaccharide (PnC) of the cell wall of Streptococcus
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pneumoniae, in a Ca2+ -dependent manner (3–6). After
complexing with a ligand such as PnC, CRP activates the
complement system (7, 8). Human CRP activates complement
in both human and murine sera (9, 10). In human serum, CRP
binds to C1q and activates the classical pathway of complement
(7). Since human CRP does not interact with murine C1q, it is
not known which pathway is utilized by human CRP to activate
murine complement (9).
The C1q-binding site of CRP is formed in and around a cleft
that is located on the opposite side of the PCh-binding site of the
CRP pentamer (3, 4). The amino acid residues which contribute
to the formation of the C1q-binding site of CRP are His38 , Glu88 ,
Asp112 , Asn158 , and Tyr175 from one subunit and Lys114 from the
neighboring subunit. Mutational analysis of these amino acids
revealed that His38 , Asp112 , and Tyr175 were critical for binding
to C1q and activating complement in human serum (11, 12).
Asp112 and Tyr175 appeared to be the C1q contact residues. Three
CRP mutants, H38R, D112N, and Y175A have been previously
identified as the mutants which displayed reduced binding to C1q
and did not activate complement in human serum (12).
Human CRP has been shown to protect mice against
lethal pneumococcal infection (13–16). Although a functioning
complement system is required for full CRP-mediated protection,
the exact mechanism of action of CRP in protecting mice against
pneumococcal infection is not known (17–19). Decades ago, it
was hypothesized that complement activation by CRP complexed
with PCh was responsible for CRP-mediated protection of mice
against pneumococcal infection (20). This hypothesis could not
be tested experimentally at the time due to the unavailability of
a CRP mutant which would bind to pneumococci but would not
activate complement in murine serum.
Previously, we tested the Y175A CRP mutant for activation
of murine complement. We reported that Y175A CRP did not
activate human complement but activated murine complement
(9). Other CRP mutants, H38R and D112N, that did not activate
human complement were not tested for murine complement
activation earlier. Here, we report that the CRP mutant H38R
does not activate murine complement either. The availability of
H38R CRP provided us with the needed tool to test the hypothesis
that complement activation by PCh-complexed CRP is critical for
CRP to protect mice against pneumococcal infection.

µl/ml). Transfected cells were cultured for 20 h at 37◦ C with 5%
CO2 . At 20 h post-transfection, ExpiCHO enhancer (6 µl/ml)
and ExpiCHO feed (240 µl/ml) were added to the transfected
cells and the culture was then transferred to 32◦ C with 8%
CO2 . The culture media containing expressed CRP mutants were
harvested 14 days post-transfection.

Purification of CRP
WT CRP was purified exactly as described previously, and the
same method was used to purify CRP mutants H38A and H38R
(21). In brief, CRP was purified by Ca++ -dependent affinity
chromatography on a PCh-Sepharose column (Pierce), followed
by gel filtration on a Superose12 column (GE Healthcare) using
the Biologic Duo Flow Protein Purification System (Bio-Rad).
Purified CRP was stored in TBS (10 mM Tris-HCl, pH 7.2,
containing 150 mM NaCl) containing 2 mM CaCl2 at 4◦ C and
was used within 10 days. The purity and pentameric structure of
CRP mutants were determined by SDS-PAGE and gel filtration.
For use in mice, purified CRP was treated with the Detoxi-Gel
Endotoxin Removing Gel (ThermoFisher Scientific) according
to manufacturer’s instructions. The concentration of endotoxin
in all CRP preparations, as determined by using the Limulus
Amebocyte Lysate kit QCL-1000 (Lonza), was <2.2 endotoxin
units per 25 µg CRP.

Murine Complement Activation Assay
First, poly-L-lysine-PnC (P-PnC) was synthesized, as described
previously (22), with some modifications. Briefly, 200 µl of 1
mg/ml PnC (Statens Serum Institute, 3459) was slowly added to
10 ml of 10 mM NaOH. Then, 10 mg of cyanuric chloride (Sigma,
C95501) was added, followed by the addition of 2 ml of polyL-lysine (200 µg/ml in H2 O), to the mixture. After adjusting
the pH to 8.2 using NaOH, the mixture was incubated for 2 h
at 4◦ C with occasional stirring. The resulting P-PnC (poly-Llysine ∼20 µg/ml and PnC ∼100 µg/ml) was stored at 4◦ C; a 1:4
dilution of this preparation was used to coat microtiter wells for
the following assays.
Binding of CRP to the PCh ligand P-PnC was evaluated as
follows: Microtiter wells were coated with P-PnC in 100 µl TBS,
overnight at 4◦ C. The unreacted sites were blocked with TBS
containing 0.5% gelatin for 1 h at room temperature. CRP, diluted
in TBS containing 2 mM CaCl2 , 0.1% gelatin and 0.02 % Tween
20 (TBS-Ca), was then added in duplicate wells and incubated for
2 h at 37◦ C. After washing the wells with TBS-Ca, bound CRP was
detected by using anti-CRP monoclonal antibody HD2.4 diluted
in TBS-Ca. HRP-conjugated goat anti-mouse IgG diluted in TBSCa was used as the secondary antibody. Color was developed
using ABTS substrate and the OD was read at 405 nm in a
plate reader.
Murine complement activation was assessed by measuring
the deposition of activated murine C3 on P-PnC-complexed
CRP, as follows: Microtiter wells were coated with P-PnC in
100 µl 10 mM phosphate buffer saline, pH 7.2 (PBS), overnight
at 4◦ C. The unreacted sites were blocked with PBS containing
1% BSA for 1 h at room temperature, followed by rinsing the
wells with buffer A (PBS containing 0.1% BSA and 1 mM
CaC12 ). CRP diluted in buffer B (buffer A containing 0.01%

MATERIALS AND METHODS
Construction and Expression of CRP
Mutants
The construction of H38A and H38R CRP mutants has been
described earlier (12). CRP mutants were expressed in CHO cells
using the ExpiCHO Expression System (ThermoFisher Scientific)
according to manufacturer’s instructions. In brief, non-adherent
ExpiCHO-S cells (Gibco) were cultured in a shaker flask at 37◦ C
with 5% CO2 . Cells (6 × 106 cells/ml) were then transfected
with mutant CRP cDNA (1 µg) using Expifectamine reagent (3.2
Abbreviations: CRP, C-reactive protein; PCh, phosphocholine; PnC,
pneumococcal C-polysaccharide; P-PnC, poly-L-lysine-conjugated PnC; WT,
wild-type.
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Mouse Protection Experiments

Tween 20) was then added in duplicate wells and incubated
for 1 h at 37◦ C. The wells were washed with buffer B and then
with buffer C (PBS containing 1% BSA, 0.15 mM CaC12 and
0.5 mM MgC12 ). Normal mouse serum (Innovative Research
IGMSC57SER), diluted 1/30 in chilled buffer C, was added to
each well and incubated for 30 min at 37◦ C, followed by washing
with buffer C. Goat anti-mouse C3 antibody (Cappel), diluted
1/750 in buffer C, was added to each well. After 1 h at 37◦ C, the
wells were washed, and developed with HRP-conjugated bovine
anti-goat IgG (Santa Cruz Biotechnology). Color was developed
using ABTS substrate and the OD was read at 405 nm in a
plate reader.

Mouse protection experiments were performed exactly as
described previously (24). In brief, mice were injected i.v. with
25 µg CRP. After 30 min, 100 µl of 3.4 × 108 CFU/ml of
pneumococci was injected. Survival of mice was recorded three
times per day for 7 days. To determine bacteremia (CFU/ml),
blood samples were collected from each surviving mouse twice
daily for the first 3 days, followed by once daily for next 2 days.
Blood was diluted and plated on blood agar plates and incubated
for 18 h at 37◦ C before the colonies were counted. The plotting
and statistical analyses of the data were done using the GraphPad
Prism 4 software. Statistical significance for survival among
the groups was determined by Log-rank test and differences in
bacteremia were analyzed by Mann-Whitney test.

Pneumococcus Binding Assay
Pneumococcus binding assay was performed exactly as described
previously (16, 23). Briefly, microtiter wells were coated with 107
CFU of pneumococci overnight at 4◦ C. The unreacted sites in
the wells were blocked with TBS containing 0.5% gelatin. CRP,
diluted in TBS-Ca, was then added to the wells for 2 h at 37◦ C.
After washing the wells with TBS-Ca, bound CRP was detected by
using anti-CRP monoclonal antibody HD2.4. HRP-conjugated
goat-anti mouse IgG was used as the secondary antibody. Color
was developed using ABTS substrate and the OD was read at
405 nm in a plate reader.

RESULTS
All experiments were performed three times, unless otherwise
mentioned, and comparable results were obtained each time.
Results of a representative experiment are shown in the figures
where the raw data (OD280 or A405 ) were used to plot the curves.

H38R CRP Does Not Activate Murine
Complement
Previously, for murine C3 deposition assays, we used CRPPnC complexes to activate complement (9). However, we
failed to generate a reliable murine C3 deposition assay using
commercially available batch of PnC at this time. Instead of
using CRP-PnC complexes, we used CRP-P-PnC complexes for
murine C3 activation. As shown (Figure 1A), H38A and H38R
CRP mutants bound to P-PnC as well as WT CRP did. In the
C3 deposition assay (Figure 1B), WT CRP activated murine C3
in a CRP concentration-dependent manner. Like WT CRP, H38A
CRP also activated murine C3 in a CRP concentration-dependent
manner. Even if the binding of WT CRP and H38A CRP to P-PnC
did not differ from each other, H38A CRP was more efficient than
WT CRP in activating murine C3. However, H38R CRP did not
result in any C3 deposition on CRP-P-PnC, suggesting that H38R
CRP was unable to activate murine complement.

Clearance of H38R CRP From Mouse
Circulation
The clearance rate of H38R CRP from the mouse blood was
determined as described previously (23). Briefly, five mice were
injected i.v. with 50 µg of H38R CRP in 100 µl TBS containing
2 mM CaCl2 through the tail vein. Blood samples were collected
from the tip of the tail after 12, 16, 20, and 24 h, and sera were
separated. The concentration of CRP in the sera was measured
by ELISA.

Mice
Male C57BL/6J mice, 8–10 weeks old, were purchased from
Jackson Laboratories and used in the protection experiments.
All animal studies have been reviewed and approved by the
University Committee on Animal Care.

H38R CRP Is Pentameric and Binds to
Pneumococci
The elution volume of H38R CRP from the gel filtration column
was identical to that of WT CRP (Figure 2A), indicating that
the molecular weight of H38R CRP was same as WT CRP. SDSPAGE analysis (Figure 2B) of H38R CRP confirmed the purity
of the preparation and showed that there was no difference in
the molecular weight of the subunits of WT and H38R CRP.
Thus, H38R CRP was pentameric. Also, the Ca2+ -dependent
binding of H38R CRP to pneumococci was similar to that of WT
CRP (Figure 2C). We have reported previously that the Ca2+ dependent binding of H38R CRP to PnC and PCh-conjugated
BSA was also similar to that of WT CRP (12).

Pneumococci
Virulent S. pneumoniae type 3, strain WU2 (obtained from Dr.
David Briles, University of Alabama, Birmingham, AL), was
cultured as described previously (23). Single use bacterial aliquot
(1 ml) of virulent stock was prepared and stored at −80◦ C. For
each experiment, an aliquot of frozen pneumococci was thawed
in 50 ml Todd-Hewitt broth containing 0.5% yeast extract and
incubated at 37◦ C with shaking at 125 rpm for 3 h and collected
from mid-log phase cultures. The culture was centrifuged at 7,500
rpm for 15 min. The bacterial pellet was washed and resuspended
in 10 ml normal saline and the volume adjusted to an absorbance
A600 = 0.29 (3.5 × 108 CFU/ml). The concentration, purity,
and viability of pneumococci was confirmed by plating on sheep
blood agar plates.

Frontiers in Immunology | www.frontiersin.org

H38R CRP Is Stable in vivo
We have reported previously that the rate of clearance of
WT CRP from mouse circulation was 0.67 µg/ml/h (23). To
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FIGURE 2 | Overall pentameric structure of H38R CRP. A representative of
three experiments is shown. (A) Elution profiles of CRP from the gel filtration
column are shown. CRP in TBS containing 2 mM CaCl2 was applied to the
column and eluted with the same buffer. Sixty fractions (0.25 ml) were
collected and protein measured (A280 ) to determine the elution volume of CRP.
(B) Denaturing SDS-PAGE of CRP. A Coomassie brilliant blue-stained gel (lane
2, WT CRP; lane 3, H38R CRP), is shown. (C) Binding of CRP to
pneumococci. Microtiter wells were coated with pneumococci. CRP diluted in
TBS-Ca was added to the wells. Bound CRP was detected by using an
anti-CRP antibody. Color was developed and the OD was read at 405 nm.

FIGURE 1 | Activation of murine complement by human CRP. A representative
of three experiments is shown. (A) Binding of CRP to P-PnC. Microtiter wells
were coated with P-PnC. CRP diluted in TBS-Ca was added to the wells.
Bound CRP was detected by using an anti-CRP antibody. Color was
developed and the OD was read at 405 nm. (B) Activation of murine C3 by
CRP complexed with P-PnC. Microtiter wells were coated with P-PnC. CRP
diluted in TBS-Ca was added to the wells. Normal mouse serum was then
added to the wells. Deposited C3 was detected by using goat anti-mouse C3
antibody. Color was developed and the OD was read at 405 nm.

control in the experiment. The median survival time (MST, the
time taken for the death of 50% of mice) for mice injected with
bacteria alone was 56 h. The MST for mice injected with H38R
CRP was 72 h. There was no statistically significant difference
between mice receiving H38R CRP and mice not receiving any
CRP. The MST for mice injected with either WT CRP or H38A
CRP could not be determined since >50% mice survived in both
groups. There was no statistically significant difference between
mice receiving either WT or H38A CRP.
Next, we determined bacteremia in each surviving mouse
(Figure 5). In mice receiving H38A CRP, bacteremia decreased,
like in WT CRP-treated mice. There was no statistically
significant difference in bacteremia in WT CRP-treated and
H38A CRP-treated mice. However, bacteremia continued to
increase in H38R CRP-treated mice, like in untreated mice, and
mice died once bacteremia was >108 CFU/ml. There was no

determine the dose of H38R CRP for in vivo use, we evaluated
the rate of clearance of H38R CRP from mouse circulation
(Figure 3). The clearance rate of H38R CRP was found to be
0.20 µg/ml/h, suggesting that the clearance of H38R CRP was not
faster than that of WT CRP and that the substitution of His38 with
Arg did not reduce the stability of H38R CRP in vivo.

H38R CRP Does Not Protect Mice Against
Pneumococcal Infection
Figure 4 shows the combined results from two separate mouse
protection experiments. H38A CRP, which was not different from
WT CRP in activating murine complement, was included as a
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FIGURE 3 | Clearance of H38R CRP from mouse circulation. Mice were
injected with 50 µg of CRP. Blood was collected at various time points, sera
separated, and the concentration of CRP measured.

statistically significant difference in bacteremia in untreated and
H38R CRP-treated mice. Combined data from survival of mice
and bacteremia suggested that H38R CRP was not protective
against pneumococcal infection and that the lethality of H38R
CRP-treated mice was due to the inability of H38R CRP to
decrease bacteremia.

FIGURE 4 | Survival curves of mice infected with pneumococci with and
without CRP. CRP was injected first; pneumococci were injected 30 min later.
The data are combined from two separate experiments with seven mice in
each group in each experiment. The p-values for the differences in the survival
curves between groups A B, A D, B C, and C D were <0.05. The p-values for
the differences in the survival curves between groups A C and B D were >0.05.

DISCUSSION
Our major findings in this study were: 1. H38R CRP, which did
not activate complement in human serum as reported previously
(12), did not activate complement in murine serum either. 2.
H38R CRP incapable of activating murine complement failed to
protect mice against lethal pneumococcal infection. The inability
of H38R CRP to protect mice against pneumococcal infection
was solely due to its inability to activate the complement system
since the H38R mutation did not reduce the stability of CRP;
H38R CRP was more stable than WT CRP in vivo. Our findings
confirm that complement activation by CRP-PCh complexes
constitute the mechanism of CRP-mediated protection (decrease
in bacteremia and increase in survival time) of mice against lethal
pneumococcal infection.
Previously, we investigated the role of the PCh-binding
site of CRP in protection of mice against pneumococcal
infection employing a CRP triple mutant, F66A/T76Y/E81A,
incapable of binding to PCh and pneumococci. Different mouse
models provided different results (23, 24). Surprisingly, in
one mouse model, CRP triple mutant protected mice against
infection despite being unable to bind to PCh, suggesting
that complement activation by CRP-PCh complexes was not
required for protection (24). Later, we found out that CRP
triple mutant, like acidic pH-treated WT CRP, had inadvertently
gained the capability to bind to any protein that was immobilized

Frontiers in Immunology | www.frontiersin.org

on a polystyrene surface, including complement factor H
(unpublished observations) (25, 26). Factor H is an inhibitor
of complement activation and pneumococci recruit factor H to
escape complement-dependent killing (27). Our current finding
that complement activation by CRP-PCh complexes is absolutely
required for protection suggests that in the previously published
protection experiments involving CRP triple mutant (incapable
of binding to PCh but capable of binding to immobilized factor
H), at some point during the decrease in bacteremia, endogenous
murine CRP might have participated in protection by binding
to PCh on pneumococci and activating the murine complement
system (24).
Human CRP activates complement in both human and
murine sera (9, 10). Human CRP binds to C1q and activates
the classical pathway of complement in human serum (7). It is
not known whether the classical pathway is the only pathway
through which human CRP can activate human complement.
Human CRP does not interact with murine C1q and, therefore,
the activation of murine complement by human CRP is not
through the classical pathway (9). The pathway through which
human CRP activates murine C3 remains undefined (9, 10).
Based on the known crosstalk among CRP, lectins, ficolins,
and pneumococci, it was proposed earlier that human CRP
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can activate complement through the lectin pathway also (9,
10, 28, 29). Irrespective of the pathway through which human
CRP activates murine complement, our data suggest that the
cleft on CRP, that accommodates the binding site for human
C1q, is critical for human CRP to activate murine complement.
However, all three amino acid residues, His38 , Asp112 , and Tyr175 ,
critical for the formation of the binding site for human C1q and
for activation of human complement, are not critical for murine
complement activation. The Y175A CRP does not activate
human complement but activates murine complement. The
H38R does not activate complement in both human and murine
sera. The D112N CRP does not activate human complement
and has not been tested for murine complement activation yet.
The role of the other amino acid residues, Glu88 and Asn158 ,
present in the CRP cleft in activating murine complement is
also unknown.
Despite several unanswered questions regarding the
mechanisms of complement activation by human CRP in
human and murine sera, we conclude that CRP cannot protect
against pneumococcal infection if CRP is unable to activate the
complement system. Also, since endogenous murine CRP has
been shown to be protective against pneumococcal infection
in another mouse model (2), we propose that the experiments
on structure-function relationships of CRP in pneumococcal
infection employing human CRP mutants should always be
conducted employing CRP knockout mice (30).
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